ClinicalTrials.gg
CompletedNCT02088541SOPRAUpdated Jan 26, 2023Results posted

Selinexor (KPT-330) in Older Patients With Relapsed AML

A Phase 2 interventional study of Selinexor and Hydroxyurea in Acute Myeloid Leukemia (AML), sponsored by Karyopharm Therapeutics Inc. Completed at 78 sites in 11 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing selinexor in Leukemia, Myeloid, Acute — 6 open to participants now, 12 under way, 2 of them phase 3. selinexor · Leukemia, Myeloid, Acute.

Enrollment
Largest of 27
317 · median 25
Started
2014
with 4 others
Phase 2
9 of 27
3 open now
Registered
1st of 27
by date

Among the 27 studies testing selinexor in Leukemia, Myeloid, Acute, this one has the largest enrollment, is one of 5 that started in 2014, is one of 9 in phase 2, and was the 1st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 27 studies testing selinexor in Leukemia, Myeloid, Acute are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing selinexor in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior therapy only, who have never undergone and who are not currently eligible for stem cell transplantation and are currently deemed unfit for intensive chemotherapy.

Read the detailed description

This is a randomized, multicenter, open-label phase 2 study of the SINE compound, selinexor given orally versus restricted investigator choice (i.e., one of three potential salvage therapies).

Participants who have never been transplant eligible, are currently deemed unfit for intensive chemotherapy, ≥ 60 years old, who have AML (except Acute Promyelocytic Leukemia: APL, AML M3) after one prior treatment of either hypomethylating agent or a regimen including Ara-C, and are meeting the inclusion and exclusion criteria will be randomized to receive either oral selinexor or physician's choice (one of three potential treatments: best supportive care (BSC) alone, or BSC + hypomethylating agent, or BSC + low dose Ara-C until disease progression, death or intolerance has occurred.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Relapsed/Refractory Acute Myeloid Leukemia
  • Acute Myeloid Leukemia
  • AML
  • Karyopharm
  • Selinexor
  • KPT-330
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 60 years with AML of any type except for acute promyelocytic leukemia (APL; AML M3), after at least 1 prior AML therapy , who have never undergone, and who are not currently eligible for, stem cell transplantation, and are currently deemed unfit for intensive chemotherapy.
  • (ECOG) ≤ 2.
  • Must have available archival or recently acquired bone marrow /aspiration or tumor tissue for central review to be eligible.
  • Relapsed or refractory AML, defined as either: recurrence of disease after a complete remission (CR), or failure to achieve CR with initial therapy.
  • Must have received at least 1 prior line of AML therapy given at standard doses and must have progressed after their most recent therapy. Prior therapy must have included: a hypomethylating agent with at least 2 cycles.
  • At least 2 weeks must have elapsed since the last anti-leukemia treatment (with the exception of hydroxyurea) before first dose in this study.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any agent within 3 weeks prior to first dose in this study.
  • Presence of central nervous system (CNS) leukemia.
  • In blast transformation of chronic myeloid leukemia (CML). Prior myelodysplastic syndrome (MDS) is acceptable; prior treatment for MDS does not count as an AML therapy.
  • Major surgery within 2 weeks of first dose of study drug. Participants must have recovered from the effects of any surgery performed greater than 2 weeks previously.
  • Concurrent active under treatment.
  • Known active virus (HBV) or C virus () infection; or known to be positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).
  • Known infection.
  • Unable to swallow tablets, or participants with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function.
  • Participants whose AML is classified as favorable according to the European LeukemiaNet (ELN) disease risk assessment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)

    Participants under protocol versions (PV) less than (\<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m\^2 (milligrams per square meter) (60 to 120 mg based on body surface area \[BSA\]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

    Drug: Selinexor

  • Experimental
    Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)

    Participants under PV \< 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m\^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

    Drug: Selinexor

  • Experimental
    Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)

    Participants under PV \>= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m\^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

    Drug: Selinexor

  • Active comparator
    Physician's Choice 1 (PV <5)

    Participants under PV \< 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.

    Drug: Hydroxyurea

  • Active comparator
    Physician's Choice 2 (PV >=5)

    Participants under PV \>= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.

    Drug: Ara-C

Interventions

  • Selinexor oral tablet.

    Also known as: KPT-330

  • Also known as: Hydroxycarbamide

  • DrugAra-C

    Ara-C Subcutaneous Injection.

    Also known as: Cytarabine, Cytosine arabinoside, Cytosar-U, Depocyt

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact.

    Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Secondary outcomes

  1. Percentage of Participants With Overall Survival of at Least 3 Months (OS3.0)

    Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

    Time frame: From randomization (Day 1) up to 3 months

  2. Percentage of Participants With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR)

    CRR was analyzed using International Working Group (IWG) 2003 criteria, as the difference in the proportions of participants with IWG results of CR. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 percentage (%) myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood absolute neutrophil count (ANC) \> 1000 cells/microliter (microL) and platelet count \> 100,000/microL, with no need for red blood cell (RBC) transfusions), and the absence of extramedullary disease.

    Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

  3. Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission (CR)

    DFS for CRR based on IWG criteria, was calculated from the first date of response of CR to the date of progression or recurrence, or date of death if progression or recurrence did not occur. Participants who discontinued prior to disease progression or recurrence or did not progress as of the time of the analysis were censored at the time of last radiologic assessment. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 % myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease.

    Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

  4. Percentage of Participants With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri)

    mCRR was defined as the point estimate of the percentage of participants who had CR, CRi, or CRp. Responses defined as per IWG 2003 response criteria: Morphologic CR:\< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.

    Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

  5. Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp)

    DFS based on IWG criteria was defined as the duration from start of the complete response achieved until disease progression or death from any cause. Responses defined by IWG 2003 Response Criteria: Morphologic CR: \< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.

    Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

  6. Percentage of Participants With Overall Response Rate (ORR)

    Overall response rate was defined as the point estimate of the percentage of participants who achieved CR (disappearance of all target and non-target lesions), partial response (PR) (\>=30 % decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions). CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. CRp; All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L) and morphologic leukemia-free state (MLFS); morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%, in absence of blasts with Auer rods, no hematologic recovery required.

    Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

  7. Duration of Response (DOR)

    DOR was calculated from date of response of CR, CRi, CRp, MLFS, or PR to date of progression or recurrence based on IWG criteria. CR: \<5% myeloblasts in bone marrow,absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL, platelet count \> 100,000/microL, no need for RBC transfusions), absence of extramedullary disease. PR: No circulating blasts, neutrophil count \> =1.0 x10\^9/L, platelet count \>= 100 x10\^9/L, \>= 50 % reduction in bone marrow blast to 6% to 25%, or blasts less than or equal to (\<=) 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), CRi; \< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS: morphologic bone marrow blast clearance to \< 5% in marrow sample, \<= 200 cells enumerated/cellularity is ≥ 10%, in absence of blasts with Auer rods, no hematologic recovery required.

    Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

  8. Percentage of Participants With Disease Control Rate (DCR)

    DCR:Point estimate of % of participants with CR,CRi,CRp,MLFS,PR, or SD for \<=4 weeks.CR:\<5% myeloblasts in bone marrow (BM),absence of circulating blasts,hematologic recovery(peripheral blood ANC \>1000 cells/microL and platelet count \>100,000/microL, no need of RBC transfusions),absence of extramedullary disease. PR:No circulating blasts,Neutrophil count \>=1.0 x10\^9/L, Platelet count \>= 100\*10\^9/L, \>=50% reduction in BM blast to 6% to 25%, or blasts \<=5% if Auer rods are present.CRp:All criteria for CR except for residual neutropenia (\<1\*10\^9/L) or thrombocytopenia(\<100 x10\^9/L),CRi;\< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS:morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%,in absence of blasts with Auer rods,no hematologic recovery required,SD:failure to achieve a response but not meeting criteria for disease progression over period of \>4 weeks.

    Time frame: Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria

  9. Duration of Disease Control Rate

    Duration of DCR calculated for all participants with DCR. CR: \< 5% myeloblasts in BM, absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL and platelet count \> 100,000/microL, no need for RBC transfusions), absence of extra medullary disease. PR: No circulating blasts, Neutrophil count \>=1.0 x 10\^9/L, Platelet count \>= 100 x 10\^9/L, \>= 50 % reduction in BM blast to 6% to 25%, or blasts \<= 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1 x 10\^9/L) or thrombocytopenia (\<100 x 10\^9/L), CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS; morphologic BM blast clearance to \< 5% in a marrow sample in which \<=200 cells enumerated/cellularity is \>= 10%, in absence of blasts with Auer rods, no hematologic recovery required and SD; failure to achieve a response but not meeting criteria for disease progression over period of \> 4 weeks.

    Time frame: Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria

  10. Change From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu]

    QoL was assessed by the FACT-Leu. FACT-Leu combines the General version of the Functional Assessment of Cancer Therapy (FACT-G) with a leukemia-specific sub-scale (17 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI; total of 31 items) was the primary measurement of interest, comprising the Physical and Functional sub-scales plus the leukemia - specific sub-scale. Each item was rated on a 5-point Likert scale. Range from 0 = (Not at all) to 4 = (Very much); therefore, the TOI had a score ranging from 0 to 124. Higher scores indicated improvement in well being. The QoL assessment was performed at baseline (prior to first dose of study treatment), Day 1 of each cycle on or after the second, and at the final visit.

    Time frame: Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)

  11. Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS)

    EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D-5-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.

    Time frame: Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)

07

Results

Posted Oct 8, 2020

Participant flow

Participant flow — Overall Study
MilestoneSelinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 1 (PV <5)Physician's Choice 2 (PV >=5)
Started71271174458
Safety population71271153945
Intent-to-treat (itt) population00118057
Completed00000
Not completed71271174458
Withdrew: Adverse event30330
Withdrew: Death5121852838
Withdrew: Lost to follow-up20100
Withdrew: Physician decision21202
Withdrew: Disease progression71231
Withdrew: Study terminated by sponsor111226
Withdrew: Withdrawal by subject329710
Withdrew: Other21311

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact.

Time frame:
Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Reported as:
Median · Days
Overall Survival
DaysSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Overall Survival94.0 (78.0 to 158.0)170.0 (111.0 to 220.0)
Statistical analysis
  • Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) vs Physician's Choice 2 (PV >=5) · Log Rank · p = 0.4221 · Hazard ratio (hr): 1.18 · 95% CI 0.79 to 1.75
SecondaryPercentage of Participants With Overall Survival of at Least 3 Months (OS3.0)

Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

Time frame:
From randomization (Day 1) up to 3 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Survival of at Least 3 Months (OS3.0)
Percentage of participantsSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Percentage of Participants With Overall Survival of at Least 3 Months (OS3.0)53.49 (43.54 to 62.44)70.73 (55.60 to 81.52)
Statistical analysis
  • Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) vs Physician's Choice 2 (PV >=5) · Log Rank · p = 0.9464
SecondaryPercentage of Participants With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR)

CRR was analyzed using International Working Group (IWG) 2003 criteria, as the difference in the proportions of participants with IWG results of CR. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 percentage (%) myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood absolute neutrophil count (ANC) \> 1000 cells/microliter (microL) and platelet count \> 100,000/microL, with no need for red blood cell (RBC) transfusions), and the absence of extramedullary disease.

Time frame:
Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR)
Percentage of participantsSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Percentage of Participants With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR)5.1 (1.9 to 10.7)0 (0.0 to 6.3)
Statistical analysis
  • Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) vs Physician's Choice 2 (PV >=5) · Cochran-Mantel-Haenszel · p = 0.0986
SecondaryMedian Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission (CR)

DFS for CRR based on IWG criteria, was calculated from the first date of response of CR to the date of progression or recurrence, or date of death if progression or recurrence did not occur. Participants who discontinued prior to disease progression or recurrence or did not progress as of the time of the analysis were censored at the time of last radiologic assessment. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 % myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease.

Time frame:
Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Reported as:
Median · Days
Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission (CR)
DaysSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission (CR)121.0 (49.0 to NA)—
SecondaryPercentage of Participants With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri)

mCRR was defined as the point estimate of the percentage of participants who had CR, CRi, or CRp. Responses defined as per IWG 2003 response criteria: Morphologic CR:\< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.

Time frame:
Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri)
Percentage of participantsSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Percentage of Participants With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri)11.9 (6.6 to 19.1)3.5 (0.4 to 12.1)
Statistical analysis
  • Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) vs Physician's Choice 2 (PV >=5) · Cochran-Mantel-Haenszel · p = 0.0844
SecondaryMedian Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp)

DFS based on IWG criteria was defined as the duration from start of the complete response achieved until disease progression or death from any cause. Responses defined by IWG 2003 Response Criteria: Morphologic CR: \< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.

Time frame:
Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Reported as:
Median · Days
Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp)
DaysSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp)175.0 (61.0 to 288.0)106.0 (NA to NA)
SecondaryPercentage of Participants With Overall Response Rate (ORR)

Overall response rate was defined as the point estimate of the percentage of participants who achieved CR (disappearance of all target and non-target lesions), partial response (PR) (\>=30 % decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions). CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. CRp; All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L) and morphologic leukemia-free state (MLFS); morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%, in absence of blasts with Auer rods, no hematologic recovery required.

Time frame:
Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Response Rate (ORR)
Percentage of participantsSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Percentage of Participants With Overall Response Rate (ORR)13.6 (8.0 to 21.1)8.8 (2.9 to 19.3)
SecondaryDuration of Response (DOR)

DOR was calculated from date of response of CR, CRi, CRp, MLFS, or PR to date of progression or recurrence based on IWG criteria. CR: \<5% myeloblasts in bone marrow,absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL, platelet count \> 100,000/microL, no need for RBC transfusions), absence of extramedullary disease. PR: No circulating blasts, neutrophil count \> =1.0 x10\^9/L, platelet count \>= 100 x10\^9/L, \>= 50 % reduction in bone marrow blast to 6% to 25%, or blasts less than or equal to (\<=) 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), CRi; \< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS: morphologic bone marrow blast clearance to \< 5% in marrow sample, \<= 200 cells enumerated/cellularity is ≥ 10%, in absence of blasts with Auer rods, no hematologic recovery required.

Time frame:
Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Reported as:
Median · Days
Duration of Response (DOR)
DaysSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Duration of Response (DOR)204.0 (117.0 to 334.0)148.0 (85.0 to NA)
SecondaryPercentage of Participants With Disease Control Rate (DCR)

DCR:Point estimate of % of participants with CR,CRi,CRp,MLFS,PR, or SD for \<=4 weeks.CR:\<5% myeloblasts in bone marrow (BM),absence of circulating blasts,hematologic recovery(peripheral blood ANC \>1000 cells/microL and platelet count \>100,000/microL, no need of RBC transfusions),absence of extramedullary disease. PR:No circulating blasts,Neutrophil count \>=1.0 x10\^9/L, Platelet count \>= 100\*10\^9/L, \>=50% reduction in BM blast to 6% to 25%, or blasts \<=5% if Auer rods are present.CRp:All criteria for CR except for residual neutropenia (\<1\*10\^9/L) or thrombocytopenia(\<100 x10\^9/L),CRi;\< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS:morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%,in absence of blasts with Auer rods,no hematologic recovery required,SD:failure to achieve a response but not meeting criteria for disease progression over period of \>4 weeks.

Time frame:
Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control Rate (DCR)
Percentage of participantsSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Percentage of Participants With Disease Control Rate (DCR)50.8 (41.5 to 60.2)40.4 (27.6 to 54.2)
SecondaryDuration of Disease Control Rate

Duration of DCR calculated for all participants with DCR. CR: \< 5% myeloblasts in BM, absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL and platelet count \> 100,000/microL, no need for RBC transfusions), absence of extra medullary disease. PR: No circulating blasts, Neutrophil count \>=1.0 x 10\^9/L, Platelet count \>= 100 x 10\^9/L, \>= 50 % reduction in BM blast to 6% to 25%, or blasts \<= 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1 x 10\^9/L) or thrombocytopenia (\<100 x 10\^9/L), CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS; morphologic BM blast clearance to \< 5% in a marrow sample in which \<=200 cells enumerated/cellularity is \>= 10%, in absence of blasts with Auer rods, no hematologic recovery required and SD; failure to achieve a response but not meeting criteria for disease progression over period of \> 4 weeks.

Time frame:
Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria
Reported as:
Median · Days
Duration of Disease Control Rate
DaysSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Duration of Disease Control Rate187.0 (125.0 to 261.0)233.0 (155.0 to 263.0)
SecondaryChange From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu]

QoL was assessed by the FACT-Leu. FACT-Leu combines the General version of the Functional Assessment of Cancer Therapy (FACT-G) with a leukemia-specific sub-scale (17 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI; total of 31 items) was the primary measurement of interest, comprising the Physical and Functional sub-scales plus the leukemia - specific sub-scale. Each item was rated on a 5-point Likert scale. Range from 0 = (Not at all) to 4 = (Very much); therefore, the TOI had a score ranging from 0 to 124. Higher scores indicated improvement in well being. The QoL assessment was performed at baseline (prior to first dose of study treatment), Day 1 of each cycle on or after the second, and at the final visit.

Time frame:
Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)
Reported as:
Mean · Units on a scale
Change From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu]
Units on a scaleSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Baseline70.5 ± 15.2075.4 ± 14.74
C2D10.5 ± 16.50-1.9 ± 15.18
C3D1-1.9 ± 16.88-5.4 ± 22.25
C4D1-1.2 ± 15.70-7.4 ± 25.41
C5D1-2.4 ± 16.841.9 ± 8.40
C6D1-3.4 ± 15.66-4.7 ± 13.20
C7D1-5.0 ± 17.21-11.8 ± 27.43
C8D1-3.9 ± 15.78-10.6 ± 7.83
C9D1-2.7 ± 7.47-8.0 ± 8.49
C10D12.4 ± 13.19-10.7 ± 12.70
C11D1-0.1 ± 8.65-10.0 ± 9.90
C12D1-3.7 ± 11.69-7.0 ± 16.97
C13D1-3.3 ± 6.40-9.0 ± NA
C14D1-4.0 ± 3.46-15.0
C15D11.5 ± 3.54-10.0 ± NA
C16D1—-15.0 ± NA
C17D1-15.0 ± NA-7.0 ± NA
C18D1-1.0 ± NA—
C19D1-12.0 ± NA—
C20D1-14.0 ± NA—
Final visit2.5 ± 17.71-1.7 ± 20.46
SecondaryChange From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS)

EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D-5-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.

Time frame:
Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)
Reported as:
Mean · Units on a scale
Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS)
Units on a scaleSelinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 2 (PV >=5)
Baseline67.9 ± 19.5163.5 ± 21.10
C2D1-7.5 ± 23.450.8 ± 15.82
C3D1-13.3 ± 25.04-5.2 ± 23.54
C4D1-6.1 ± 20.80-5.0 ± 11.46
C5D1-0.9 ± 20.83-2.0 ± 15.31
C6D1-11.2 ± 25.90-1.4 ± 24.10
C7D1-3.7 ± 23.914.0 ± 10.84
C8D10.1 ± 16.775.0 ± 9.35
C9D14.6 ± 13.255.0 ± 10.80
C10D10.7 ± 18.586.3 ± 15.48
C11D10.8 ± 18.55-5.0 ± 21.21
C12D13.3 ± 16.63-5.0 ± 28.28
C13D16.7 ± 20.2110.0 ± NA
C14D16.7 ± 25.6615.0 ± NA
C15D13.5 ± 30.41-10.0 ± NA
C16D1—20.0 ± NA
C17D125.0 ± NA-5.0 ± NA
C18D125.0 ± NA—
C19D130.0 ± NA—
C20D135.0 ± NA—

Adverse events

Collected over From start of study drug administration to 30 days after last dose of study drug (approximately 48 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)24/71 (33.8%)58/71 (81.7%)71/71 (100%)
Selinexor 60mg (PV<5) (Equivalent to 35 mg/m^2)3/27 (11.1%)15/27 (55.6%)27/27 (100%)
Selinexor 60mg (PV >=5) (Equivalent to 35 mg/m^2)28/115 (24.3%)89/115 (77.4%)113/115 (98.3%)
Physician's Choice 1 (PV <5)7/39 (17.9%)25/39 (64.1%)37/39 (94.9%)
Physician's Choice 2 (PV >=5)9/45 (20%)30/45 (66.7%)40/45 (88.9%)
Most frequent serious events
Showing 10 of 137
Most frequent serious events
EventSelinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)Selinexor 60mg (PV<5) (Equivalent to 35 mg/m^2)Selinexor 60mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 1 (PV <5)Physician's Choice 2 (PV >=5)
Febrile NeutropeniaBlood and lymphatic system disorders16/714/2720/1158/3916/45
PneumoniaInfections and infestations10/714/2710/1154/393/45
Nervous System DisordersNervous system disorders8/711/2715/1150/391/45
SepsisInfections and infestations8/711/273/1153/391/45
Lung InfectionInfections and infestations3/711/271/1153/390/45
DehydrationMetabolism and nutrition disorders5/710/272/1151/390/45
HyperglycaemiaMetabolism and nutrition disorders5/710/270/1150/390/45
FatigueGeneral disorders1/710/278/1150/390/45
AnaemiaBlood and lymphatic system disorders2/710/272/1150/393/45
PyrexiaGeneral disorders4/711/277/1152/391/45
Most frequent other events
Showing 10 of 541
Most frequent other events
EventSelinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)Selinexor 60mg (PV<5) (Equivalent to 35 mg/m^2)Selinexor 60mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 1 (PV <5)Physician's Choice 2 (PV >=5)
NauseaGastrointestinal disorders41/7116/2768/11513/398/45
Decreased AppetiteGeneral disorders41/7112/2761/1159/397/45
DiarrhoeaGastrointestinal disorders17/7113/2741/1158/396/45
FatigueGeneral disorders33/7113/2750/11515/3913/45
ThrombocytopeniaBlood and lymphatic system disorders29/717/2738/11518/3911/45
AnaemiaBlood and lymphatic system disorders20/717/2729/11517/3910/45
ConstipationGastrointestinal disorders20/718/2725/11516/3915/45
VomitingGastrointestinal disorders19/7110/2730/1157/396/45
HyponatraemiaMetabolism and nutrition disorders26/716/2725/1153/391/45
PyrexiaGeneral disorders8/715/2728/11513/3913/45

Baseline characteristics

Safety Population included all participants who received any amount of study treatment and was the primary population for the analysis of safety outcome measure.

Age, Continuous
Age, Continuous(years)Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2)Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 1 (PV <5)Physician's Choice 2 (PV >=5)Total
Mean72.4 ± 6.4973.2 ± 4.6473.6 ± 5.9972.6 ± 5.2474.2 ± 5.9273.2 ± 5.90
Sex: Female, Male
Sex: Female, Male(Participants)Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2)Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 1 (PV <5)Physician's Choice 2 (PV >=5)Total
Female2611461715115
Male4516692230182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2)Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 1 (PV <5)Physician's Choice 2 (PV >=5)Total
Hispanic or Latino4394626
Not Hispanic or Latino6523933431246
Unknown or Not Reported21131825
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of Participants)Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA)Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2)Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)Physician's Choice 1 (PV <5)Physician's Choice 2 (PV >=5)Total
White6722953937260
Black or African American313007
Asian020002
Other01150622
Unknown112026
08

Study locations

78 sites
  • Jonsson Comprehensive Cancer Center / University of California, Los Angeles
    Los Angeles, California 90024, United States
  • Sutter Oncology & Hematology
    Sacramento, California 95816, United States
  • Stanford Cancer Institute / Stanford University
    Stanford, California 94304, United States
  • Colorado Blood Cancer Institute/Sarah Cannon Research Institute
    Denver, Colorado 80218, United States
  • Yale Cancer Center / Yale University
    New Haven, Connecticut 06510, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Winship Cancer Institute / Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Sidney Kimmel Comprehensive Cancer Center / John Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109-0944, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Westchester Medical Center / New York Medical College
    Hawthorne, New York 10532, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • New York Presbyterian Hospital / Weill Cornell Medical College
    New York, New York 10065, United States
  • Duke Cancer Care
    Durham, North Carolina 27705, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Milton S. Hershey Medical Center / Penn State
    Hershey, Pennsylvania 17033, United States
  • Tennessee Oncology/Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt-Ingram Cancer Center / Vanderbilt University
    Nashville, Tennessee 37215, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030, United States
  • Texas Transplant Institute/Sarah Cannon Research Institute
    San Antonio, Texas 78229, United States
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta
    Edmonton, Alberta T6G 2G3, Canada
  • Sir Mortimer B. Davis Jewish General Hospital / McGill University
    Montreal, Quebec H2W1S6, Canada
  • Aarhus University Hospital
    Aarhus, Denmark
  • Department of Haematology, National University Hospital, Rigshospitalet
    Copenhagen, Denmark
  • Herlev Hospital
    Herlev, Denmark
  • Odense University Hospital, Department of Hematology
    Odense, Denmark
  • CHU Bordeaux- Hôpital Haut Lévêque
    Bordeaux, France
  • Centre Hospitalier Lyon
    Lyon, France
  • Hopital Saint Louis
    Paris, France
  • Hôpital Avicenne
    Paris, France
  • Institut Universitaire du Cancer Toulouse
    Toulouse, France
  • Stellvertretende Klinikleiterin Charité, Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Ev. Diakonie-Krankenhaus Gemeinnutzige GMBH Medizinische Klinik 2
    Bremen, Germany
  • UNIVERSITÄTSKLINIKUM TU DRESDEN Medizinische Klinik und Poliklinik I,
    Dresden, Germany
  • University Hospital Frankfurt
    Frankfurt, Germany
  • Medizinische Hochschule Hannover (Hannover Medical School) Dept. of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation
    Hanover, Germany
  • Abteilung Hämatologie, internistische Onkologie und Hämostaseologie
    Leipzig, Germany
  • UNIVERSITY HOSPITAL OF MÜNSTER Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster
    Münster, Germany
  • Universitätsklinikum Ulm
    ULM, Germany
  • Sororka MC
    Beer Sheva, 85025, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Wolfson Medical Center
    Holon, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petach Tikva, 4941492, Israel
  • Tel Aviv Sourasky Medical Centre
    Tel Aviv, Israel
  • Chaim Sheba Medical Center
    Tel Hashomer, 52621, Israel
  • AOU Ospedali Riuniti di Ancona
    Ancona, Italy
  • A.O Spedali Civili di Brescia
    Brescia, Italy
  • AORN Cardarelli / UOSC di Ematologia con TMO
    Naples, Italy
  • AMC, Academisch Medisch Centrum Afdeling Klinische Hematologie
    Amsterdam, Netherlands
  • VU University Medical Center
    Amsterdam, Netherlands
  • Universitair Medisch Centrum Groningen Department of Haematology
    Groningen, Netherlands
  • Radboud University Medical Center Department of Haematology (476)
    Nijmegen, Netherlands
  • Erasmus MC, location Daniel den Hoed
    Rotterdam, Netherlands
  • University Medical Center Utrecht
    Utrecht, Netherlands
  • Isala Kliniecken Zwolle
    Zwolle, Netherlands
  • Wojewódzki Szpital Specjalistyczny im. M. Kopernika, Klinika Hematologii
    Lodz, Poland
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych
    Olsztyn, Poland
  • Instytut Hematologii i Transfuzjologii
    Warszawa, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu
    Wroclaw, Poland
  • ICO Badalona
    Badalona, 08916, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Universitario de Salamanca Servicio de Hematologia
    Salamanca, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, Spain
  • Northwick Park Hospital
    Harrow, England HA1 3UJ, United Kingdom
  • Royal Liverpool University Hospital, Dept of Cellular and Molecular Physiology, Molecular and Clinical Cancer Medicine
    Liverpool, Lancashire L7 8XP, United Kingdom
  • Royal Marsden NHS Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • University Hospital Wales
    Cardiff, Wales CF14 4XW, United Kingdom
  • Hull and East Yorkshire Hospitals NHS Trust Queens Centre for Oncology and Haematology
    Hull, Yorkshire HU3 2JZ, United Kingdom
  • Ninewells Hospital and Medical School NHS Tayside
    Dundee, DD1 9SY, United Kingdom
  • Plymouth Hospitals NHS Trust/Derriford Hospital
    Plymouth, United Kingdom
09

References and documents

Publications

  • Sweet K, Bhatnagar B, Dohner H, Donnellan W, Frankfurt O, Heuser M, Kota V, Liu H, Raffoux E, Roboz GJ, Rollig C, Showel MM, Strickland SA Jr, Vives S, Tang S, Unger TJ, Joshi A, Shen Y, Alvarez MJ, Califano A, Crochiere M, Landesman Y, Kauffman M, Shah J, Shacham S, Savona MR, Montesinos P. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2021 Dec;62(13):3192-3203. doi: 10.1080/10428194.2021.1950706. Epub 2021 Jul 29. PubMed 34323164 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Jan 2018 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2020, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2014
First posted
Mar 17, 2014
Start
Mar 2014
Primary completionActual
Jan 8, 2018
CompletionActual
Jan 8, 2018
Results first posted
Oct 8, 2020
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02088541
Responsible party
Sponsor
First posted
Mar 17, 2014
Start date
Mar 2014
Primary completion
Jan 8, 2018
Completion
Jan 8, 2018
Results posted
Oct 8, 2020
Last update
Jan 26, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion